Ad
IONS - Ionis Pharmaceuticals Stock Trading
About | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
Not available
Quote | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
| Last: | $40.94 |
|---|---|
| Change Percent: | -1.7% |
| Open: | $41.73 |
| Close: | $41.65 |
| High: | $41.82 |
| Low: | $40.74 |
| Volume: | 252,784 |
| Last Trade Date Time: | 06/09/2023 03:00:00 am |
News | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
-
2023-06-08 03:57:44 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) prices $500M aggregate principal amount of 1.75% convertible senior notes due 2028 in a private placement to qualified institutional buyers. The initial purchasers are granted an option to purchase, within the 13-...
-
2023-06-07 12:02:37 ET Major market averages were seeking direction during Wednesday's midday session ahead of CPI data and the Fed's policy meeting next week. Tracking individual stocks, Stitch Fix ( NASDAQ: SFIX ) shares rose and Casey's General Stores ( NASDAQ: CASY )...
Message Board Posts | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $IONS News Article - Biogen and Alcyone Therapeutics Announce License and Collaboration | whytestocks | investorshangout | 01/04/2023 9:00:53 PM |
| whytestocks: $IONS News Article - Ionis announces eplontersen met co-primary and secondary endpoints | whytestocks | investorshangout | 06/21/2022 5:35:59 PM |
| whytestocks: $IONS News Article - Ionis partner Biogen announces that results from Phase 3 VALOR stu | whytestocks | investorshangout | 06/03/2022 5:05:51 PM |
| whytestocks: $IONS News Article - Ionis to hold first quarter 2022 financial results webcast | whytestocks | investorshangout | 04/20/2022 6:05:51 PM |
| whytestocks: $IONS News Article - Ionis announces positive data for ETESIAN Phase 2b study of antise | whytestocks | investorshangout | 04/04/2022 12:25:53 PM |
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
Ad
